Mounting scientific interest in psychedelics has achieved the highest levels of government. The Food and Drug Administration in 2018 granted psilocybin “breakthrough therapy” status for main depressive disorder, a designation that paved how for medical trials.“Psychedelic medicine is beginning to transcend partisan politics in a way that few